Aclaris Therapeutics is in a precarious liquidity position, with cash of $19.2M in 2026Q2 against a quarterly operating burn of ~$20M, implying less than one quarter of runway without additional financing. Revenue has contracted sharply (down 58.19% YoY to $1....
Price trend, volume and key moving averages
Trailing total returns as of 9/24/2026, which may include dividends or other distributions. Benchmark is S&P 500 (^GSPC).
Recent results and news deserve attention only when they alter the forward view.
| Quarter | EPS (Act vs Est) | Revenue (Act vs Est) |
|---|---|---|
Q3 2026Latest Aug 6, 2026 | -$0.15+6.3% vs -$0.16 | $2M+17.8% vs $1M |
Q2 2026 May 7, 2026 | -$0.15+6.3% vs -$0.16 | $2M+51.0% vs $1M |
Q1 2026 Feb 26, 2026 | -$0.16-6.7% vs -$0.15 | $1M-37.5% vs $2M |
Q4 2025 Nov 6, 2025 | -$0.12+7.7% vs -$0.13 | $3M+59.3% vs $2M |
Aclaris (ACRS) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price increase in the near term.
WAYNE, Pa., Sept. 03, 2026 (GLOBE NEWSWIRE) -- Aclaris Therapeutics, Inc. (NASDAQ: ACRS), a clinical-stage biopharmaceutical company focused on developing novel product candidates for immuno-inflammatory diseases, today announced that on Thursday, September 10, 2026, at 2:45 PM ET, Aclaris' Chief Executive Officer Dr. Neal Walker will participate in a fireside chat during the 2026 Cantor Global Healthcare Conference in New York, NY.
Deutsche Bank AG purchased a new stake in Aclaris Therapeutics, Inc. (NASDAQ: ACRS) in the second quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The firm purchased 1,040,955 shares of the biotechnology company's stock, valued at approximately $5,507,000. Deutsche Bank AG owned about 0.75% of
The consensus price target hints at a 69.2% upside potential for Aclaris (ACRS). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.
Benchmark ACRS against direct peers instead of judging its metrics in isolation.
Key metrics vs top competitors for Aclaris Therapeutics, Inc. (ACRS)
| Company | Price | Market Cap | P/E Ratio | Rev Growth (1Y) | Net Margin | ROE | Div Yield |
|---|---|---|---|---|---|---|---|
| $5.26 | $734.63M | -9.92 | -58.19% | -829.58% | -50.2% | — | |
| $57.66 | $1.91B | -5.93 | -43.89% | -287.84% | -37.99% | — | |
| $138.70 | $8.92B | -67.66 | -89.41% | 29.4% | 12.03% | — | |
| $21.53 | $2.22B | -20.70 | 20.6% | -67.85% | -23.43% | — | |
| $26.39 | $3.32B | -8.02 | -4.26% | -386.32% | -87.98% | — | |
| $6.50 | $178.89M | -13.83 | 10.2% | -8.95% | -20.23% | — |
Aclaris Therapeutics, Inc. (ACRS) vs competitors — business, growth, and fundamentals comparison against the closest industry rivals.
Verify the primary filings, follow material updates, and answer the remaining questions.
Aclaris Therapeutics, Inc. (ACRS) SEC filings — annual & quarterly reports (10-K, 10-Q)
Aug 6, 2026·SEC
Aug 6, 2026·SEC
Jun 4, 2026·SEC
Get notified when ACRS posts new earnings or crosses analyst targets
Free. No account needed. Unsubscribe any time.
Aclaris Therapeutics, Inc. (ACRS) stock FAQ — growth, dividends, profitability & financials explained
Aclaris Therapeutics, Inc. (ACRS) reported $8.2M in revenue for fiscal year 2025.
Aclaris Therapeutics, Inc. (ACRS) saw revenue decline by 58.2% over the past year.
Aclaris Therapeutics, Inc. (ACRS) reported a net loss of $75.7M for fiscal year 2025.
Aclaris Therapeutics, Inc. (ACRS) has a return on equity (ROE) of -50.2%. Negative ROE indicates the company is unprofitable.
Aclaris Therapeutics, Inc. (ACRS) had negative free cash flow of $62.2M in fiscal year 2025, likely due to heavy capital investments.
